Dieser Artikel kommt von finanztreff.de

Press, Release 20.06.2017 - 07:56:39

Press Release: Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval Novartis International AG / Novartis RTH258 (brolucizumab) demonstrates robust visual gains in nAMD patients with a majority on a 12-week injection interval .

Press Release: Novartis RTH258 (brolucizumab) -2-

weiterlesen... @ finanztreff.de